{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:46:41Z","timestamp":1787838401073,"version":"build-2784847793"},"reference-count":38,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2005,8,1]],"date-time":"2005-08-01T00:00:00Z","timestamp":1122854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,8,1]],"date-time":"2005-08-01T00:00:00Z","timestamp":1122854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2005,8]]},"DOI":"10.1136\/ard.2004.032268","type":"journal-article","created":{"date-parts":[[2005,1,28]],"date-time":"2005-01-28T01:23:47Z","timestamp":1106875427000},"page":"1150-1157","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":584,"title":["Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial"],"prefix":"10.1016","volume":"64","author":[{"given":"C","family":"Antoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G G","family":"Krueger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"de Vlam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Birbara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Beutler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Guzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L T","family":"Dooley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Kavanaugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard.2004.032268_bib1","first-page":"69","article-title":"Psoriasis and psoriatic arthritis. Dermatological and rheumatological co-operative clinical report","volume":"146","author":"Biondi","year":"1989","journal-title":"Acta Derm Venerol Suppl (Stockh)"},{"key":"10.1136\/ard.2004.032268_bib2","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0733-8635(05)70376-4","article-title":"Population based epidemiologic study of psoriasis with emphasis on quality of life assessment","volume":"14","author":"Koo","year":"1996","journal-title":"Dermatol Clin"},{"key":"10.1136\/ard.2004.032268_bib3","first-page":"1247","article-title":"The epidemiology of psoriatic arthritis in Olmsted Country, Minnesto, USA, 1982\u20131991","volume":"27","author":"Shbeeb","year":"2000","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2004.032268_bib4","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1136\/ard.40.4.366","article-title":"Arthritis in psoriasis","volume":"40","author":"Green","year":"1981","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2004.032268_bib5","unstructured":"National Psoriasis Foundation. Benchmark survey on psoriasis and psoriatic arthritis. New National Psoriasis Foundation survey shows that psoriasis diminishes quality of life for millions. 2002. Available at http:\/\/www.psoriasis.org\/news\/news\/2001\/200104_npfsurvey.php (accessed 14 February 2005)."},{"key":"10.1136\/ard.2004.032268_bib6","first-page":"518","article-title":"Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid","volume":"24","author":"Partsch","year":"1997","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2004.032268_bib7","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1002\/1529-0131(200006)43:6<1244::AID-ANR7>3.0.CO;2-2","article-title":"Macrophage-derived cytokine and nuclear factor \u03baB p65 expression in synovial membrane and skin of patients with psoriatic arthritis","volume":"43","author":"Danning","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2004.032268_bib8","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","article-title":"Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial","volume":"356","author":"Mease","year":"2000","journal-title":"Lancet"},{"key":"10.1136\/ard.2004.032268_bib9","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/art.20335","article-title":"Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression","volume":"50","author":"Mease","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2004.032268_bib10","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1046\/j.1365-2133.2001.04089.x","article-title":"Treatment of psoriatic arthritis with antitumor necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate","volume":"144","author":"Ogilvie","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1136\/ard.2004.032268_bib11","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/art.10671","article-title":"Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation","volume":"47","author":"Antoni","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2004.032268_bib12","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1136\/ard.59.6.428","article-title":"Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study","volume":"59","author":"den Bosch Van","year":"2000","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2004.032268_bib13","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1136\/ard.61.3.207","article-title":"Repeated infusions of infliximab, a chimeric anti-TNF\u03b1 monoclonal antibody, in patients with active spondyloarthropathy: one year follow up","volume":"61","author":"Kruithof","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2004.032268_bib14","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/art.11201","article-title":"Efficacy of infliximab in resistant psoriatic arthritis","volume":"49","author":"Salvarani","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2004.032268_bib15","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1136\/ard.2003.006775","article-title":"Treatment of refractory psoriatic arthritis with infliximab: a 12 month observational study of 16 patients","volume":"63","author":"Feletar","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2004.032268_bib16","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/art.20967","article-title":"Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)","volume":"52","author":"Antoni","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2004.032268_bib17","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/S0140-6736(00)04954-0","article-title":"Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial","volume":"357","author":"Chaudhari","year":"2001","journal-title":"Lancet"},{"key":"10.1136\/ard.2004.032268_bib18","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2004.032268_bib19","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1002\/art.1780391210","article-title":"Comparison of sulphasalazine and placebo in the treatment of psoriatic arthritis: a Department of Veterans Affairs Cooperative study","volume":"39","author":"Clegg","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2004.032268_bib20","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000250839","article-title":"Severe psoriasis: oral therapy with a new retinoid","volume":"157","author":"Fredriksson","year":"1978","journal-title":"Dermatologica"},{"key":"10.1136\/ard.2004.032268_bib21","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","article-title":"Therapetuic efficacy of multiple intravenous infusions of anti-tumor necrosis factor [alpha] monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis","volume":"41","author":"Maini","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2004.032268_bib22","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1002\/art.1780200308","article-title":"An immunofluorescent method using Crithidia luciliae to detect antibodies to double-stranded DNA","volume":"20","author":"Crowe","year":"1977","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2004.032268_bib23","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1126\/science.161.3843.806","article-title":"Deoxyribonucleic acid antibody: a method to detect its primary interaction with deoxyribonucleic acid","volume":"161","author":"Wold","year":"1968","journal-title":"Science"},{"key":"10.1136\/ard.2004.032268_bib24","first-page":"316","article-title":"Tests with A.R.E. of 1 or more. In,","author":"Conover","year":"1980","journal-title":"Practical nonparametric statistics"},{"key":"10.1136\/ard.2004.032268_bib25","first-page":"42","article-title":"Interpretation: norm-based. In:","volume":"8","author":"Ware","year":"1994","journal-title":"SF-36 physical and mental health summary scales: a user's manual"},{"issue":"Suppl I","key":"10.1136\/ard.2004.032268_bib26","first-page":"391","article-title":"How much improvement in functional status is considered important by patients with active psoriatic arthritis: applying the outcome measures in rheumatoid arthritis clinical trials (OMERACT) group guidelines [abstract]","volume":"63","author":"Mease","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2004.032268_bib27","series-title":"Primer on the rheumatic diseases","first-page":"233","article-title":"Disease-modifying antirheumatic drugs. In: Klippel JH, Crofford LJ, Stone JH, Weyand, CM, eds","author":"Boumpas","year":"2001"},{"key":"10.1136\/ard.2004.032268_bib28","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/1529-0131(200104)45:2<151::AID-ANR168>3.0.CO;2-T","article-title":"Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis","volume":"45","author":"Husted","year":"2001","journal-title":"Arthritis Care Res"},{"key":"10.1136\/ard.2004.032268_bib29","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1002\/art.1780401021","article-title":"Mortality studies in psoriatic arthritis. Results from a single outpatient clinic. Causes and risk of death","volume":"40","author":"Wong","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2004.032268_bib30","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/1529-0131(199806)41:6<1103::AID-ART18>3.0.CO;2-N","article-title":"Mortality studies in psoriatic arthritis. Results from a single outpatient center. Prognostic indicators for death","volume":"41","author":"Gladman","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2004.032268_bib31","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/rheumatology\/30.4.245","article-title":"Psoriatic arthritis (PsA): a clinical, immunological and radiological study of 180 patients","volume":"30","author":"Torre","year":"1991","journal-title":"Br J Rheumatol"},{"key":"10.1136\/ard.2004.032268_bib32","first-page":"1842","article-title":"Comparison of disability and quality of life in rheumatoid and psoriatic arthritis","volume":"28","author":"Sokoll","year":"2001","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2004.032268_bib33","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1002\/art.20253","article-title":"Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial","volume":"50","author":"Kaltwasser","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2004.032268_bib34","unstructured":"St Clair EW. Disease-modifying antirheumatic drugs. In: Klippel JH, Crofford LJ, Stone JH, Weyand CM, eds. Primer on the rheumatic diseases, 12th ed. Atlanta, Georgia: Arthritis Foundation 2001:599\u2013605."},{"key":"10.1136\/ard.2004.032268_bib35","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/0002-9343(91)90667-M","article-title":"Methotrexate and histologic hepatic abnormalities: a meta-analysis","volume":"90","author":"Whiting-O'Keefe","year":"1991","journal-title":"Am J Med"},{"key":"10.1136\/ard.2004.032268_bib36","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0190-9622(99)70112-X","article-title":"Psoriasis causes as much disability as other major medical diseases","volume":"41","author":"Rapp","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1136\/ard.2004.032268_bib37","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","article-title":"Infliximab (chimeric anti-tumour necrosis factor \u03b1 monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial","volume":"354","author":"Maini","year":"1999","journal-title":"Lancet"},{"key":"10.1136\/ard.2004.032268_bib38","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000349672442894X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000349672442894X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.2004.032268","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T05:20:43Z","timestamp":1736140843000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000349672442894X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2005,8]]}},"alternative-id":["S000349672442894X"],"URL":"https:\/\/doi.org\/10.1136\/ard.2004.032268","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2005,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.2004.032268","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 Copyright 2005 by Annals of the Rheumatic Diseases, Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}